GABAeron, Inc.
San Francisco, CA · Biotech · Private
Small molecule therapeutics that protect GABAergic neurons from apoE-induced damage in Alzheimer's disease
- Grants
- $5.7M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4 | $292,422 | |
| Federal grant | Department of Health and Human Services · Phase I · Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease | $342,592 | |
| Federal grant | Department of Health and Human Services · Phase II · Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4 | $1,930,668 | |
| Federal grant | Department of Health and Human Services · Phase II · Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease | $1,079,582 | |
| Federal grant | Department of Health and Human Services · Phase II · Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4 | $948,584 | |
| Federal grant | Department of Health and Human Services · Phase II · Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease | $1,086,082 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2605 | CONCARLO HOLDINGS, LLC | — | $450K |
| 2606 | GSNO THERAPEUTICS, INC. | — | — |
| 2607 | ANEURYST, INC. | — | — |
| 2608 | GABAeron, Inc. | — | — |
| 2609 | Curza Inc | — | $367K |
| 2610 | BreStem Therapeutics, Inc. | — | $300K |
| 2611 | VERAMORPH LLC | — | $262K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.